Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer in the Era of Personalized Medicine Reply

被引：0
|
作者：
Kawaguchi, Tomoya [1 ,2 ]
Ando, Masahiko [3 ]
Kubo, Akihito [4 ,5 ]
机构：
[1] Osaka City Univ, Osaka 558, Japan
[2] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Osaka, Japan
[3] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan
[4] Aichi Med Univ, Sch Med, Nagakute, Aichi, Japan
[5] Natl Hosp Org, Nagoya Med Ctr, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 05期
关键词：
TRIAL; CHEMOTHERAPY;
D O I：
10.1200/JCO.2014.58.5315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：526 / U205
页数：3
相关论文
共 50 条
  • [1] Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer in the Era of Personalized Medicine
    Biswas, Bivas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (05) : 524 - 524
  • [2] Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer
    Papadimitrakopoulou, Vassiliki A.
    Soria, Jean-Charles
    Jappe, Annette
    Jehl, Valentine
    Klimovsky, Judith
    Johnson, Bruce E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) : 1594 - 1601
  • [3] Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
    Kawaguchi, Tomoya
    Ando, Masahiko
    Asami, Kazuhiro
    Okano, Yoshio
    Fukuda, Masaaki
    Nakagawa, Hideyuki
    Ibata, Hidenori
    Kozuki, Toshiyuki
    Endo, Takeo
    Tamura, Atsuhisa
    Kamimura, Mitsuhiro
    Sakamoto, Kazuhiro
    Yoshimi, Michihiro
    Soejima, Yoshifumi
    Tomizawa, Yoshio
    Isa, Shun-ichi
    Takada, Minoru
    Saka, Hideo
    Kubo, Akihito
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18) : 1902 - 1908
  • [4] Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Owonikoko, Taofeek K.
    Behera, Madhusmita
    Subramanian, Janakiraman
    Saba, Nabil F.
    Kono, Scott A.
    Gal, Anthony A.
    Sica, Gabriel
    Harvey, R. Donald
    Chen, Zhengjia
    Klass, Carmen M.
    Shin, Dong M.
    Fu, Haian
    Sun, Shi-yong R.
    Govindan, Ramaswamy
    Khuri, Fadlo R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 369 - 372
  • [5] An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
    Horgan, A. M.
    Bradbury, P. A.
    Amir, E.
    Ng, R.
    Douillard, J. Y.
    Kim, E. S.
    Shepherd, F. A.
    Leighl, N. B.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (08) : 1805 - 1811
  • [6] Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
    Shao, Yu-Yun
    Shau, Wen-Yi
    Lin, Zhong-Zhe
    Chen, Ho-Min
    Kuo, Raymond
    Yang, James Chih-Hsin
    Lai, Mei-Shu
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 106 - 114
  • [7] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA
    Kim, Y. G.
    Lee, E. K.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A514 - A514
  • [8] Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer
    Chouaid, C.
    Moser, A.
    Coudray-Omnes, C.
    Vergnenegre, A.
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2008, 25 (09) : 1096 - 1103
  • [9] The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    Mlak, Radoslaw
    Kucharczyk, Tomasz
    Kowalski, Dariusz M.
    Krzakowski, Maciej
    Milanowski, Janusz
    [J]. RESPIRATION, 2011, 82 (04) : 341 - 350
  • [10] Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line
    Leighl, N. B.
    [J]. CURRENT ONCOLOGY, 2012, 19 : S52 - S58
12345